Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

The Fidelity MSCI Health Care Index ETF (FHLC) charges a much lower 0.08% expense ratio versus 0.37% for iShares U.S. Pharmaceuticals (IHE) while holding 338 stocks versus IHE’s 56, reducing single-stock concentration risk. IHE outperformed on a one-year basis (60% total return as of Aug. 10, 2026) but appears more concentrated (top 5 ~57% of assets) with Eli Lilly (~21%) and J&J (~22%) dominating returns. The article favors FHLC for long-term diversification and cost efficiency despite lower recent performance.

Analysis

This is not a fundamental healthcare call; it is a wrapper/flow story. The only real market mechanism is that fee-sensitive allocators tend to migrate to the cheapest broad vehicle, which gradually supports diversified healthcare ownership while leaving concentrated pharma funds more dependent on a narrow set of mega-cap winners. That means the incremental bid likely accrues to broad sector proxies such as XLV/VHT/FHLC over months, not over a single session.

Within pharma, concentration cuts both ways: if LLY continues to compound, a concentrated fund can beat a diversified one even with a higher fee because the winners dominate index math. But the same structure makes the ETF more fragile to one-off regulatory or pricing shocks at LLY or JNJ, which can translate into faster multiple compression than in a broader basket. In other words, the article highlights a volatility transfer problem more than a return-generation problem.

Contrarian view: the fee spread is small enough that it is unlikely to drive institutional capital on its own, so the headline probably overstates the durability of any rotation. The bigger latent catalyst is not ETF expense ratios but whether healthcare leadership broadens beyond LLY/JNJ; if breadth improves, diversified funds gain relative to concentrated pharma, and if it doesn’t, the concentrated fund keeps its embedded convexity. Falsifier for a relative-long-broad-healthcare thesis would be continued underweight breadth with LLY/JNJ extending leadership and pharma multiples holding in a risk-off tape.

Key Decisions for Investors

• If adding passive healthcare exposure, prefer FHLC or XLV over IHE on a 3-12 month horizon; the lower fee plus broader constituent base should capture incremental inflows with less single-name risk.
• Relative-value idea: long XLV / short XPH (or IHE if borrow is available) only on a sharp LLY-led healthcare rally; target 2-4% spread compression over 1-3 months, with the short leg hedging concentration risk rather than expressing a bearish sector view.
• Buy LLY on weakness rather than via a concentrated ETF if the goal is to own the secular winner; the ETF wrapper dilutes upside from the dominant name while still leaving exposure to a valuation reset if pricing/margin headlines worsen.
• Avoid using IHE as a tactical vehicle into healthcare until the market confirms breadth expansion; if LLY or JNJ disappoints on earnings/guidance, IHE should underperform FHLC/XLV more than the sector itself.